Anti-CD160 in Oncology

Discovered by Dr Armand BENSUSSAN (Director of the Centre for Skin Research, Inserm UMR 976, University Paris Diderot, Saint-Louis Hospital) and Dr Philippe Le Bouteiller (Centre for Pathophysiology Toulouse-Purpan, Inserm UMR 1043 CNRS 5282 UMR University of Toulouse III Paul Sabatier), the CD160 receptor is involved in neo-angiogenesis regulation as well as in the control of immunity.

Beyond endothelial vascular cells, CD160 is also expressed on the surface of circulating immune cells, such as some NK and T cells sub-populations to which it modulates the activity. Early studies have shown that anti-CD160 prevents tumor escape by activating Natural Killer cells. Combined with other immune checkpoint inhibitors, such as the anti-PD-1 antibodies it also helps to prevent T-cell exhaustion. Based on these results, ELSALYS BIOTECH is currently evaluating anti-CD160 efficacy in several solid tumors.

Anti-CD160 shows also a competitive profile, notably in B-cell chronic lymphocytic leukemia (B-CLL), and preclinical proof-of-concept has been already obtained in melanoma and fibrosarcoma models (anti-CD160 combined with chemotherapy results in a significant reduction in tumor burden and prolonged survival of animals). Using a bispecific antibody, ElsaLys Biotech intends to rely on CD-160 to selectively eliminate tumor cells in Chronic Lymphocytic Leukemia.